These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 34309133)

  • 1. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Sorscher S; Ansley K; Delaney SD; Ramkissoon S
    Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    Sorscher S
    Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
    Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    LaRose M; Manji GA; Bates SE
    Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
    Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
    Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
    Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
    J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
    [No Abstract]   [Full Text] [Related]  

  • 11. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
    Yurgelun MB; Chittenden AB; Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Qian ZR; Welch MW; Brais LK; Da Silva A; Bui JL; Yuan C; Li T; Li W; Masuda A; Gu M; Bullock AJ; Chang DT; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar MD; Wollison BM; Khalaf N; Perez K; Syngal S; Aguirre AJ; Hahn WC; Meyerson ML; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Nowak JA; Wolpin BM
    Genet Med; 2019 Jan; 21(1):213-223. PubMed ID: 29961768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rosen MN; Goodwin RA; Vickers MM
    World J Gastroenterol; 2021 May; 27(17):1943-1958. PubMed ID: 34007132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
    Vyas O; Leung K; Ledbetter L; Kaley K; Rodriguez T; Garcon MC; Saif MW
    Anticancer Drugs; 2015 Feb; 26(2):224-6. PubMed ID: 25304989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    Golan T; Atias D; Stossel C; Raitses-Gurevich M
    Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.